DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A strong ...

Medical device company DexCom (NASDAQ:DXCM) in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company ...

25 analysts are following DexCom and have set target prices ranging from $82.0 to $110.0 per share. On average, they have ...

The medical instruments industry is currently undergoing a transformative phase, thanks to the rapid adoption of generative ...

DexCom Inc. closed 34.58% short of its 52-week high of $132.26, which the company reached on May 17th.

Shares of DexCom Inc. DXCM shed 1.11% to $84.11 Tuesday, on what proved to be an all-around mixed trading session for the ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose biosensing, today announced the promotion of ...

DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins. Check out why I am lowering my rating on DXCM from buy to hold.

Insulet beat first-quarter profit estimates on Thursday, buoyed by strong demand for its wearable insulin pumps, sending shares up 7% in extended trading.

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products ...

Dexcom (NASDAQ:DXCM) announced today that it expanded its partnership with Oura, officially launching an integration with ...